Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features

International Journal of Molecular Sciences

Volumn 14, Issue 8, 2013, Pages 15655-15668

  Shi, Xiao Peng ^a   Miao, Shan ^b   Wu, Yin ^a   Zhang, Wei ^b   Zhang, Xiao Fang ^a   Ma, Hua Zhao ^c   Xin, Hai Li ^d   Feng, Juan ^a   Wen, Ai Dong ^a   Li, Yan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Military Simulation Center   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; Epithelial mesenchymal transition; Resistance; Resveratrol; Tamoxifen

Indexed keywords

RESVERATROL; SMAD PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MCF-7 CELLS; SIGNAL TRANSDUCTION; SMAD PROTEINS; STILBENES; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84881062200     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140815655     Document Type: Article

References (35)

1. Jemal, A.; Siegel, R.; Ward, '2009. CA Cancer J. Clin. 2009, 59, 225-249.
2. Miller, W.R.; Bartlett, J.M.; Canney, P.; Verrill, M. Hormonal therapy for postmenopausal breast cancer: The science of sequencing. Breast Cancer Res. Treat. 2007, 103, 149-160.
3. Perey, L.; Paridaens, R.; Hawle, H.; Zaman, K.; Nolé, F.; Wildiers, H.; Fiche, M.; Dietrich, D.; Clément, P.; Köberle, D.; et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol. 2007, 18, 64-69.
4. Gutierrez, M.C.; Detre, S.; Johnston, S.; Mohsin, S.K.; Shou, J.; Allred, D.C.; Schiff, R.; Osborne, C.K.; Dowsett, M. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 2005, 23, 2469-2476.
5. Holm, C.; Rayala, S.; Jirström, K.; Stål, O.; Kumar, R, Landberg, G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J. Natl. Cancer Inst. 2006, 98, 671-680.
6. Kirkegaard, T.; Witton, C.J.; McGlynn, L.M.; Tovey, S.M.; Dunne, B.; Lyon, A.; Bartlett, J.M. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 2005, 207, 139-146.
7. Riggins, R.B.; Schrecengost, R.S.; Guerrero, M.S.; Bouton, A.H. Pathways to tamoxifen resistance. Cancer Lett. 2007, 256, 1-24.
8. Bachleitner-Hofmann, T.; Pichler-Gebhard, B.; Rudas, M.; Gnant, M.; Taucher, S.; Kandioler, D.; Janschek, E.; Dubsky, P.; Roka, S.; Sporn, E.; Jakesz, R. Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin. Cancer Res. 2002, 8, 3427-3432.
9. Kuske, B.; Naughton, C.; Moore, K.; Macleod, K.G.; Miller, W.R.; Clarke, R.; Langdon, S.P.; Cameron, D.A. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr. Relat. Cancer 2006, 13, 1121-1133.
10. Yang, J.; Weinberg, R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell 2008, 14, 818-829.
11. Peinado, H.; Olmeda, D.; Cano, A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat. Rev. Cancer 2007, 7, 415-428.
12. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871-890.
13. Peña, C.; García, J.M.; Silva, J.; García, V.; Rodríguez, R.; Alonso, I.; Millán, I.; Salas, C.; de Herreros, A.G.; Muñoz, A.; Bonilla, F. E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: Clinicopathological correlations. Hum. Mol. Genet. 2005, 14, 3361-3370.
14. Uchikado, Y.; Natsugoe, S.; Okumura, H.; Setoyama, T.; Matsumoto, M.; Ishigami, S.; Aikou, T. Slug Expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 2005, 11, 1174-1180.
15. Arumugam, T.; Ramachandran, V.; Fournier, K.F.; Wang, H.; Marquis, L.; Abbruzzese, J.L.; Gallick, G.E.; Logsdon, C.D.; McConkey, D.J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69, 5820-5828.
16. Shintani, Y.; Okimura, A.; Sato, K.; Nakagiri, T.; Kadota, Y.; Inoue, M.; Sawabata, N.; Minami, M.; Ikeda, N.; Kawahara, K.; et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann. Thorac. Surg. 2011, 92, 1794-1804.
17. Creighton, C.J.; Li, X.; Landis, M.; Dixon, J.M.; Neumeister, V.M.; Sjolund, A.; Rimm, D.L.; Wong, H.; Rodriguez, A.; Herschkowitz, J.I.; et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 2009, 106, 13820-13825.
18. Hiscox, S.; Jiang, W.G.; Obermeier, K.; Taylor, K.; Morgan, L.; Burmi, R.; Barrow, D.; Nicholson, R.I. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int. J. Cancer 2006, 118, 290-301.
19. Saiko, P.; Szakmary, A.; Jaeger, W.; Szekeres, T.Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad?. Mutat Res. 2008, 658, 68-94.
20. Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224, 274-283.
21. Dong, Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat. Res. 2007, 523-524, 145-150.
22. Kim, M.Y.; Trudel, L.J.; Wogan, G.N. Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation. Anticancer Res. 2009, 29, 3733-3740.
23. Holme, A.L.; Pervaiz, S. Resveratrol in cell fate decisions. J. Bioenerg. Biomembr. 2007, 39, 59-63.
24. Singh, N.; Nigam, M.; Ranjan, V.; Sharma, R.; Balapure, A.K.; Rath, S.K. Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells. J. Pharmacol. Sci. 2009, 109, 473-485.
25. Filomeni, G.; Graziani, I.; Rotilio, G.; Ciriolo, M.R. trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr. 2007, 2, 295-305.
26. Garvin, S.; Ollinger, K.; Dabrosin, C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006, 231, 113-122.
27. Scheel, C.; Eaton, E.N.; Li, S.H.; Chaffer, C.L.; Reinhardt, F.; Kah, K.J.; Bell, G.; Guo, W.; Rubin, J.; Richardson, A.L.; Weinberg, R.A. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145, 926-940.
28. Engelman, J.A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9, 550-562.
29. Ryan, P.D.; Goss, P.E. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist 2006, 11, 718-731.
30. Zavadil, J.; Böttinger, E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24, 5764-5774.
31. Radisky, D.C. miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype. Breast Cancer Res. 2011, 13, 110, doi:10.1186/bcr2885
32. Zhang, W.; Feng, M.; Zheng, G.; Chen, Y.; Wang, X.; Pen, B.; Yin, J.; Yu, Y.; He, Z. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem. Biophys. Res. Commun. 2012, 417, 679-685.
33. Rho, J.K.; Choi, Y.J.; Lee, J.K.; Ryoo, B.Y.; Na, I.I.; Yang, S.H.; Kim, C.H.; Lee, J.C. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009, 63, 219-226.
34. Patel, B.; Patel, S.; Hoffman, R. Inhibition of cyclo-oxygenase-2 expression in mouse macrophages by 4-(3-methyl-but-1-enyl)-3,5,3',4'-tetrahydroxystilbene, a resveratrol derivative from peanuts. Phytother. Res. 2005, 19, 552-555.
35. Kundu, J.K.; Shin, Y.K.; Kim, S.H.; Surh, Y.J. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 2006, 27, 1465-1474.